Abstract
The aim of this study was to investigate gonadal-protective properties of thalidomide in a mouse model of chemotherapy-induced ovarian failure. Administration of thalidomide before alkylating chemotherapy preserved ovarian follicles and lead to the resumption of normal estrous cyclicity.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Retracted Publication
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / therapeutic use
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cell Count
-
Cytoprotection / drug effects
-
Disease Models, Animal
-
Down-Regulation
-
Drug Evaluation, Preclinical
-
Female
-
Gonads / drug effects
-
Gonads / pathology
-
Mice
-
Mice, Inbred C57BL
-
Ovary / drug effects*
-
Ovary / pathology
-
Primary Ovarian Insufficiency / chemically induced*
-
Primary Ovarian Insufficiency / pathology
-
Primary Ovarian Insufficiency / prevention & control*
-
Thalidomide / administration & dosage
-
Thalidomide / therapeutic use*
Substances
-
Angiogenesis Inhibitors
-
Thalidomide